Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$273.88 USD
-2.45 (-0.89%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $274.09 +0.21 (0.08%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Alnylam Pharmaceuticals, Inc. [ALNY]
Reports for Purchase
Showing records 61 - 80 ( 421 total )
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q22 Results; Positive Momentum Ahead of Key Catalysts on ATTR Amyloidosis, HBV, and Hypertension Programs
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
RNAi Pipeline Firing on All Cylinders; Multiple Datasets in Potential Blockbuster Programs Expected in 2023; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Results; Executing Well in a Challenging Environment; Lowering PT to $415 on Stargardt Delay
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
More Good News on TTR Franchise Emerges With Compelling Subgroup Data From Phase 3 APOLLO-B Program; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Additional Positive Data Emerges on Key Programs Including ONPATTRO in ATTR and Cemdisiran in IgAN; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Heart of Gold; APOLLO-B Meets Primary Endpoint; Provides Positive Read-Through to HELIOS-B; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Announces Positive Data on Partnered Complement Program, Approval of AMVUTTRA; APOLLO-B Data in Spotlight; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P